https://www.selleckchem.com/pr....oducts/dl-buthionine
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with -positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced -positive NSCLC is unclear. We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced -positive NSCLC who had received no previous systemic treatment for metastatic disease. The pri
Aimer
Commentaire
Partagez
